BACKGROUND: Electronic blood pressure (BP) measurement devices are the preferred choice of patients owing to their user-friendly nature; however, there is a requirement to investigate the accuracy and reliability of these devices. The objective of this study is to evaluate the accuracy of the Omron M6 upper-arm BP device against the mercury sphygmomanometer in adults and obese adults according to the International Protocol criteria. METHODS: One hundred and twenty-one patients, older than 30 years of age, were studied and classified on the basis of the range of the International Protocol. BP measurements at the upper arm with the Omron M6 were compared with the results obtained by two trained observers using a mercury sphygmomanometer. Nine sequential BP measurements were taken. A total of 33 participants were selected for each validation study. During the validation study, 99 measurements were performed on 33 participants for comparison. The first phase was performed on 15 participants, and if the device passed this phase, 18 more participants were selected. Having a two-fold purpose, this study was conducted on both adult and obese adult patients. RESULTS: Mean discrepancies and standard deviations of the monitor-mercury sphygmomanometer were 1.1+/-4.0 mmHg for systolic BP (SBP) and -0.5+/-3.5 mmHg for diastolic BP (DBP) in the adult group. The device passed phase 1 in 15 participants. In phase 2.1, out of a total of 99 comparisons, 88, 96, and 97 for SBP, and 88, 98, and 99 for DBP were <5, <10, and <15 mmHg, respectively. Mean discrepancies and standard deviations of the monitor-mercury sphygmomanometer were 1.7+/-4.8 mmHg for SBP and -0.8+/-4.3 mmHg for DBP in the obese adult group. The device passed phase 1 in 15 participants. In phase 2.1, out of a total of 99 comparisons, 82, 90, and 97 for SBP, and 80, 97, and 99 for DBP were <5, <10, and <15 mmHg, respectively. It was found that the Omron M6 automatic monitor, which measures BP at the upper arm, produced results in accordance with the criteria of phases 2.1 and 2.2 in both SBP and DBP, when applied to adults and to obese adults. CONCLUSION: It was concluded that the Omron M6 device, which measures BP at the upper arm, was deemed to be in accordance with the International Protocol criteria and can be recommended for use by adults and obese adults.
BACKGROUND: Electronic blood pressure (BP) measurement devices are the preferred choice of patients owing to their user-friendly nature; however, there is a requirement to investigate the accuracy and reliability of these devices. The objective of this study is to evaluate the accuracy of the Omron M6 upper-arm BP device against the mercury sphygmomanometer in adults and obese adults according to the International Protocol criteria. METHODS: One hundred and twenty-one patients, older than 30 years of age, were studied and classified on the basis of the range of the International Protocol. BP measurements at the upper arm with the Omron M6 were compared with the results obtained by two trained observers using a mercury sphygmomanometer. Nine sequential BP measurements were taken. A total of 33 participants were selected for each validation study. During the validation study, 99 measurements were performed on 33 participants for comparison. The first phase was performed on 15 participants, and if the device passed this phase, 18 more participants were selected. Having a two-fold purpose, this study was conducted on both adult and obese adult patients. RESULTS: Mean discrepancies and standard deviations of the monitor-mercury sphygmomanometer were 1.1+/-4.0 mmHg for systolic BP (SBP) and -0.5+/-3.5 mmHg for diastolic BP (DBP) in the adult group. The device passed phase 1 in 15 participants. In phase 2.1, out of a total of 99 comparisons, 88, 96, and 97 for SBP, and 88, 98, and 99 for DBP were <5, <10, and <15 mmHg, respectively. Mean discrepancies and standard deviations of the monitor-mercury sphygmomanometer were 1.7+/-4.8 mmHg for SBP and -0.8+/-4.3 mmHg for DBP in the obese adult group. The device passed phase 1 in 15 participants. In phase 2.1, out of a total of 99 comparisons, 82, 90, and 97 for SBP, and 80, 97, and 99 for DBP were <5, <10, and <15 mmHg, respectively. It was found that the Omron M6 automatic monitor, which measures BP at the upper arm, produced results in accordance with the criteria of phases 2.1 and 2.2 in both SBP and DBP, when applied to adults and to obese adults. CONCLUSION: It was concluded that the Omron M6 device, which measures BP at the upper arm, was deemed to be in accordance with the International Protocol criteria and can be recommended for use by adults and obese adults.
Authors: Daniel Sabater-Hernández; Pablo Sánchez-Villegas; José P García-Corpas; Pedro Amariles; José Sendra-Lillo; María J Faus Journal: Int J Clin Pharm Date: 2011-04-27
Authors: Beverly B Green; Melissa L Anderson; Andrea J Cook; Kelly Ehrlich; Yoshio N Hall; Clarissa Hsu; Dwayne Joseph; Predrag Klasnja; Karen L Margolis; Jennifer B McClure; Sean A Munson; Mathew J Thompson Journal: J Gen Intern Med Date: 2022-03-03 Impact factor: 6.473
Authors: Daniel Sabater-Hernández; Alejandro De La Sierra; Pablo Sánchez-Villegas; Fidelina M Santana-Pérez; Luisa Merino-Barber; María J Faus Journal: J Clin Hypertens (Greenwich) Date: 2012-03-05 Impact factor: 3.738
Authors: Beverly B Green; Melissa L Anderson; Jerry Campbell; Andrea J Cook; Kelly Ehrlich; Sarah Evers; Yoshio N Hall; Clarissa Hsu; Dwayne Joseph; Predrag Klasnja; Karen L Margolis; Jennifer B McClure; Sean A Munson; Mathew J Thompson Journal: Contemp Clin Trials Date: 2019-01-08 Impact factor: 2.226
Authors: Caroline Hd Fall; Judith B Borja; Clive Osmond; Linda Richter; Santosh K Bhargava; Reynaldo Martorell; Aryeh D Stein; Fernando C Barros; Cesar G Victora Journal: Int J Epidemiol Date: 2010-09-17 Impact factor: 7.196
Authors: Lisa-Marie Walther; Roland von Känel; Nadja Heimgartner; Claudia Zuccarella-Hackl; Guido Stirnimann; Petra H Wirtz Journal: Front Endocrinol (Lausanne) Date: 2022-07-22 Impact factor: 6.055
Authors: Deepti Gurdasani; Tommy Carstensen; Segun Fatumo; Guanjie Chen; Chris S Franklin; Javier Prado-Martinez; Heleen Bouman; Federico Abascal; Marc Haber; Ioanna Tachmazidou; Iain Mathieson; Kenneth Ekoru; Marianne K DeGorter; Rebecca N Nsubuga; Chris Finan; Eleanor Wheeler; Li Chen; David N Cooper; Stephan Schiffels; Yuan Chen; Graham R S Ritchie; Martin O Pollard; Mary D Fortune; Alex J Mentzer; Erik Garrison; Anders Bergström; Konstantinos Hatzikotoulas; Adebowale Adeyemo; Ayo Doumatey; Heather Elding; Louise V Wain; Georg Ehret; Paul L Auer; Charles L Kooperberg; Alexander P Reiner; Nora Franceschini; Dermot Maher; Stephen B Montgomery; Carl Kadie; Chris Widmer; Yali Xue; Janet Seeley; Gershim Asiki; Anatoli Kamali; Elizabeth H Young; Cristina Pomilla; Nicole Soranzo; Eleftheria Zeggini; Fraser Pirie; Andrew P Morris; David Heckerman; Chris Tyler-Smith; Ayesha A Motala; Charles Rotimi; Pontiano Kaleebu; Inês Barroso; Manj S Sandhu Journal: Cell Date: 2019-10-31 Impact factor: 41.582